Dr. Bill Hunter is the Founding Member and CEO of Canary Medical, a medical data
company focused on the development and commercialization of its patented
implantable sensor technology and complementary data and analytics ecosystem.
Bill brings more than 30 years of experience in healthcare as a former practicing
physician, serial medtech entrepreneur and chief executive. He is a lifelong inventor
with over 200 patents and patent applications. He was involved in the discovery and
development of the TAXUS® Coronary Drug-Eluting Stent, the Zilver PTX®
Peripheral Drug-Eluting Stent, paclitaxel-eluting balloons, and the Quill® barbed
wound closure device.
Bill holds a Doctor of Medicine from University of British Columbia, a Master of Science
from University of British Columbia and a Bachelor of Science from McGill University.

Sanjay Kakkar, MD, MSc, MPH (Chief Executive Officer) is a biotech and medtech entrepreneur with 30 years of experience in multinational, early-stage and high growth enterprises. He has a track record of building innovative companies in the life sciences industries in Europe, Asia and the US and advancing novel technologies for the improvement of human health. Prior to joining Tensive, he served as CEO at Tranquis, Peptilogics, Armetheon, and Trigen (which he also co-founded), and was the founder and chairman of Jai Medica. Before becoming a serial entrepreneur, he held R&D roles at Pharmacia (now Pfizer) and Novartis. Sanjay received his medical degree from King’s College, University of London, holds a Master’s degree in healthcare management from Harvard University and a Master’s degree in preventive cardiology from Imperial College.

Margherita Tamplenizza, Ph.D. (co-founder; Chief Regulatory Officer) founded the biological section at the Advanced Biomaterial platform of Fondazione Filarete and she has launched several innovation projects in the field of Life Sciences and Silver Economy for companies associated to Assolombarda, the largest territorial association of the entire entrepreneurial system in Italy. Previously, Margherita has worked in The Interdisciplinary Centre for Nanostructured Materials and Interfaces (CIMaINa) at the University of Milan where she depth her experience on cell-material interaction. She obtained her Ph.D. in Molecular and Cellular Physiology at the University of Milan and the Paracelsus Medical University of Salzburg (Austria) and she also worked at the University of Innsbruck (Austria) and the Italian Institute for Auxology for biomedicine projects. She trained on Manufacturing of Advanced Therapy Medicinal Product and she obtained her Master degree as Qualified Person of Pharmaceutical Laboratories in 2014. Margherita is an author of 15 peer- reviewed articles and a co-inventor of 4 patents.

Alberto Cantaluppi, MD (Chief Medical Officer) is a senior executive with strong background in Medicine, Pharmaceuticals, Medical Devices, Renal Therapy, Diagnostics, Bioscience, Cardiovascular Medicine, and Healthcare Services.
Alberto had full P&L responsibility and holds expertise in Sales and Marketing, Merger and Acquisition Integration, Governmental Affairs and Public Policies, Negotiation, Strategy and Organizational Design, Turnaround, Divestiture, Restructuring, Legal Split, Commissionaire and Toll Manufacturing Model, and Team Dynamics.

Alessia Zanelli (Board member and investor) is a successful entrepreneur and investor in the life sciences sector. Dr. Zanelli began her career in 2000 as Commercial Director of the Italian company Comecer, specialized in the design, engineering, manufacturing and support of advanced containment and aseptic processing systems for the pharmaceutical and nuclear medicine industries. Dr. Zanelli was promoted to General Manager in 2007 and Chief Executive Officer in 2011. She created an “exit” opportunity for the company’s shareholders by initiating and leading M&A negotiations with the Canadian ATS Group (advanced automation systems), which ultimately acquired Comecer in 2019. Since then, Dr. Zanelli has served as a Board member and investor, either directly or as a club deal member, in companies such as Tensive, Cellply (advanced analytical tools for in-depth characterization of cancer immunotherapies, cell therapies and cell biotherapies), Medendi (precision healthcare for cancer, through advanced molecular diagnostics, such as genomic and proteomic analyses, and personalized therapeutic guidance based on tumor molecular profiling) and Cristallina Holding S.p.A. (mineral waters).

Diana Saraceni is Co-Founder & General Partner at Panakes, a Venture Capital firm dedicated to early-stage investments in Life Sciences primarily in Europe and the US. With over 20 years of Venture Capital experience, she has also co-founded and managed 360 Capital Partners, another leading pan-European Venture Capital firm. She has led investments in a significant number of companies all over Europe, not only in the Life Sciences sector, and generated several exits as IPO and M&A transactions. Diana is also part of several committees in Europe and in the US for public/private grants and awards allocation to start-ups. She also follows several portfolios in neuroscience, oncology, endoscopy, tissue regeneration, ophthalmology and pain.

Dr. Canady is a highly respected physician and surgeon who is board certified in Plastic Surgery, Otolaryngology/Head and Neck Surgery and Sleep Medicine. He was a tenured Professor of Surgery, Otolaryngology, and Orthopedics (Hand) at the University of Iowa Hospitals for 21 years before transitioning to an executive role in the Healthcare Industry with Johnson and Johnson. While in this position he was a Vice President of Medical Affairs and a member of the Global Management Board for a group of J&J companies based out of Southern California. In this role he interfaced with global thought leaders and professional societies around the world. He engaged with every major regulatory body around the world and helped guide company regulatory approaches, technical and safety assessments, strategic investments and go-to-market business models. He is very widely published with multiple peer reviewed journal articles and book chapters and has presented widely both in the United States and internationally. As a Past President of the American Society of Plastic Surgeons he has always maintained his voice as an advocate for patients in the clinic or in business settings as well as during his annual charity surgical missions to developing countries.